REFERENCES
1. Negash R, Li E, Jacque N, Novicoff W, Evans SJM. Owner experience and veterinary involvement with unlicensed GS-441524 treatment of feline infectious peritonitis: a prospective cohort study. Front Vet Sci. 2024;11:1377207.
2. Yates MK, Seley-radtke KL. The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: complex modifications to the nucleoside scaffold. Antiviral Res. 2019;162:5-21.
3. Jordheim LP, Durantel D, Zoulim F, Dumontet C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat Rev Drug Discov. 2013;12:447-64.
4. Rasmussen HB, Thomsen R, Hansen PR. Nucleoside analog GS‐441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid‐19. Pharmacol Res Perspect. 2022;10:e00945.
5. Gordon CJ, Walker SM, Tchesnokov EP, et al. Mechanism and spectrum of inhibition of a 4’-cyano modified nucleotide analog against diverse RNA polymerases of prototypic respiratory RNA viruses. J Biol Chem. 2024;300:107514.
6. Coggins S, Cerna P. Pharmacologic approaches to feline infectious peritonitis. Today’s Veterinary Practice. 2025. Available from: https://todaysveterinarypractice.com/pharmacology/pharmacologic-approaches-to-feline-infectious-peritonitis/ [Last accessed on 8 Jun 2026].
7. Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) Is mediated by the viral polymerase and the proofreading exoribonuclease. mBio. 2018;9:e00221-18.
8. Rasmussen HB, Jürgens G, Thomsen R, et al. Cellular uptake and intracellular phosphorylation of GS-441524: implications for its effectiveness against COVID-19. Viruses. 2021;13:1369.
9. Siegel D, Hui HC, Doerffler E, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem. 2017;60:1648-61.
10. Yan VC, Muller FL. Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment. ACS Med Chem Lett. 2020;11:1361-6.
12. Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531:381-5.
13. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017;9:eaal3653.
15. Pedersen NC. A review of feline infectious peritonitis virus infection: 1963-2008. J Feline Med Surg. 2009;11:225-58.
16. Kent MS, Karchemskiy S, Culp WTN, et al. Longevity and mortality in cats: a single institution necropsy study of 3108 cases (1989-2019). PLoS ONE. 2022;17:e0278199.
17. Pedersen NC. Serologic studies of naturally occurring feline infectious peritonitis. Am J Vet Res. 1976;37:1449-54.
18. Tasker S, Addie DD, Egberink H, et al. Feline infectious peritonitis: european advisory board on cat diseases guidelines. Viruses. 2023;15:1847.
19. Kipar A, May H, Menger S, Weber M, Leukert W, Reinacher M. Morphologic features and development of granulomatous vasculitis in feline infectious peritonitis. Vet Pathol. 2005;42:321-30.
20. Legendre AM, Kuritz T, Galyon G, Baylor VM, Heidel RE. Polyprenyl immunostimulant treatment of cats with presumptive non-effusive feline infectious peritonitis in a field study. Front. Vet. Sci. 2017;4.
21. Fischer Y, Ritz S, Weber K, Sauter-louis C, Hartmann K. Randomized, placebo controlled study of the effect of propentofylline on survival time and quality of life of cats with feline infectious peritonitis. J Vet Intern Med. 2011;25:1270-6.
22. Ritz S, Egberink H, Hartmann K. Effect of feline interferon-omega on the survival time and quality of life of cats with feline infectious peritonitis. J Vet Intern Med. 2007;21:1193-7.
23. Santoro MG, Carafoli E. Remdesivir: from ebola to COVID-19. Biochem Biophys Res Commun. 2021;538:145-50.
24. World Health Organization. Ebola Outbreak 2014-2016 - West Africa. Ebola Virus Disease: Situation Report. Available from: https://www.who.int/emergencies/situations/ebola-outbreak-2014-2016-West-Africa [Last accessed on 8 Jun 2026].
25. Mulangu S, Dodd LE, Davey RT, et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019;381:2293-303.
26. GILEAD. Gilead donates remdesivir for Ebola Clinical Trial in the Democratic Republic of the Congo. 2025. Available from: https://www.gilead.com/company/company-statements/2025/gilead-donates-remdesivir-for-ebola-clinical-trial-in-the-democratic-republic-of-the-congo [Last accessed on 8 Jun 2026].
27. Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019;169:104541.
28. Murphy BG, Perron M, Murakami E. The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet Microbiol. 2018;219:226-33.
29. Pedersen NC, Perron M, Bannasch M, et al. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg. 2019;21:271-81.
30. Coggins SJ, Norris JM, Malik R, et al. Outcomes of treatment of cats with feline infectious peritonitis using parenterally administered remdesivir, with or without transition to orally administered GS-441524. J Vet Intern Med. 2023;37:1772-83.
31. Cosaro E, Pires J, Castillo D, Murphy BG, Reagan KL. Efficacy of oral remdesivir compared to GS-441524 for treatment of cats with naturally occurring effusive feline infectious peritonitis: a blinded, non-inferiority study. Viruses. 2023;15:1680.
32. Green J, Syme H, Tayler S. Thirty-two cats with effusive or non-effusive feline infectious peritonitis treated with a combination of remdesivir and GS-441524. J Vet Intern Med. 2023;37:1784-93.
33. Dickinson PJ, Bannasch M, Thomasy SM, et al. Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis. J Vet Intern Med. 2020;34:1587-93.
34. Krentz D, Zenger K, Alberer M, et al. Curing cats with feline infectious peritonitis with an oral multi-component drug containing GS-441524. Viruses. 2021;13:2228.
35. Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295:6785-97.
36. Choy K, Wong AY, Kaewpreedee P, et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020;178:104786.
37. Eastman RT, Roth JS, Brimacombe KR, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent. Sci. 2020;6:672-83.
38. Chua K, Conti RM. Policy implications of the orphan drug designation for remdesivir to treat COVID-19. JAMA Intern Med. 2020;180:1273.
39. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA. 2020;324:1048-57.
40. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569-78.
41. Sarpatwari A, Kaltenboeck A, Kesselheim AS. Missed opportunities on emergency remdesivir use. JAMA. 2020;324:331.
42. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious diseases society of america guidelines on the treatment and management of patients with COVID-19 (September 2022). Clin Infect Dis. 2024;78:e250-349.
43. Jones S, Novicoff W, Nadeau J, Evans S. Unlicensed GS-441524-like antiviral therapy can be effective for at-home treatment of feline infectious peritonitis. Animals. 2021;11:2257.
44. Guidance for industry - small entities compliance guide - designation of new animal drugs for minor uses or minor species. Available from: https://www.fda.gov/media/79363/download [Last accessed on 8 Jun 2026].
45. Roy M, Jacque N, Novicoff W, Li E, Negash R, Evans SJM. Unlicensed molnupiravir is an effective rescue treatment following failure of unlicensed GS-441524-like therapy for cats with suspected feline infectious peritonitis. Pathogens. 2022;11:1209.
46. Office UA, Oregon D of. January 27, 2025. 2025. Federal law enforcement seizes $4 million in property and proceeds from Texas Woman for smuggling and distributing unapproved animal drugs. Available from: https://www.justice.gov/usao-or/pr/federal-law-enforcement-seizes-4-million-property-and-proceeds-texas-woman-smuggling-and [Last accessed on 8 Jun 2026].
47. Kent AM, Guan S, Jacque N, Novicoff W, Evans SJM. Unlicensed antiviral products used for the at-home treatment of feline infectious peritonitis contain GS-441524 at significantly different amounts than advertised. J Am Vet Med Assoc. 2024;262:489-97.
48. FDA Announces position on use of compounded GS-441524 to treat FIP. 2024. Available from: https://www.fda.gov/animal-veterinary/cvm-updates/fda-announces-position-use-compounded-gs-441524-treat-fip [Last accessed on 8 Jun 2026].
49. Compounding animal drugs from bulk drug substances: guidance for industry. 2022. Available from: https://www.fda.gov/media/132567/download?attachment [Last accessed on 8 Jun 2026].
51. Wong CKH, Lau KTK, Au ICH, Xiong X, Lau EHY, Cowling BJ. Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2022;74:1450-8.
52. Finn A, Jindal A, Andrea SB, Selvaraj V, Dapaah-afriyie K. Association of treatment with remdesivir and 30-day hospital readmissions in patients hospitalized with COVID-19. Am J Med Sci. 2022;363:403-10.
53. Sanderson T, Hisner R, Donovan-banfield I, et al. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes. Nature. 2023;623:594-600.
54. Tempestilli M, Caputi P, Avataneo V, et al. Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19. J Antimicrob Chemother. 2020;75:2977-80.
55. Greenhalgh T, Sivan M, Perlowski A, Nikolich JŽ. Long COVID: a clinical update. Lancet. 2024;404:707-24.
56. Wanakumjorn P, Kimura K, Castillo D, et al. Mesenchymal stem/stromal cell therapy improves immune recovery in a feline model of severe coronavirus infection. Stem Cells Transl Med. 2025;14:szaf025.
57. Zhang S. A much-hyped COVID-19 drug is almost identical to a black-market cat cure. The Atlantic. 2020. Available from: https://www.theatlantic.com/science/archive/2020/05/remdesivir-cats/611341/ [Last accessed on 8 Jun 2026].
58. Ciortea D, Matei MN, Debita M, et al. Cardiac manifestations and emerging biomarkers in multisystem inflammatory syndrome in children (MIS-C): a systematic review and meta-analysis. Life. 2025;15:805.
59. Reardon S. New NIH office to reduce use of animals in research. Science. 2025. Available from: https://www.science.org/content/article/new-nih-office-reduce-use-animals-research [Last accessed on 8 Jun 2026].
60. Attipa C, Warr AS, Epaminondas D, et al. Emergence and spread of feline infectious peritonitis due to a highly pathogenic canine/feline recombinant coronavirus. bioRxiv. 2024;2023.11.08.566182.
61. Olarte-Castillo XA, Choi A, Frazier LE, Whittaker G. Rethinking the drivers of coronavirus virulence and pathogenesis: toward an understanding of the dynamic world of mutations, indels, and recombination within the species alphacoronavirus-1. 2024.
62. Cook S, Wittenburg L, Yan VC, et al. An optimized bioassay for screening combined anticoronaviral compounds for efficacy against feline infectious peritonitis virus with pharmacokinetic analyses of GS-441524, remdesivir, and molnupiravir in cats. Viruses. 2022;14:2429.
63. Sase O. Molnupiravir treatment of 18 cats with feline infectious peritonitis: a case series. J Vet Intern Med. 2023;37:1876-80.
64. Reagan KL, Brostoff T, Pires J, Rose A, Castillo D, Murphy BG. Open label clinical trial of orally administered molnupiravir as a first-line treatment for naturally occurring effusive feline infectious peritonitis. J Vet Intern Med. 2024;38:3087-94.
65. Černá P, Wittenburg L, Hawley J, Willis M, Siegenthaler B, Lappin MR. Pharmacokinetics of molnupiravir in cats with naturally occurring feline infectious peritonitis. Pathogens. 2025;14:666.
66. Clark T, Coggins S, Korman R, King J, Malik R. Treatment of feline infectious peritonitis in cats with molnupiravir: clinical observations and outcomes for 54 cases. Aust Vet J. 2025;103:339-53.
67. Allinder M, Tynan B, Martin C, et al. Uroliths composed of antiviral compound GS-441524 in 2 cats undergoing treatment for feline infectious peritonitis. J Vet Intern Med. 2024;38:370-4.
